Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 4/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | TOP1 | P11387 | 2/20 | 0.43 |
| ▸ | TOP2A | P11388 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12212362 | 0.90 | ALDH1A1 (0.54) | LMNATSHRKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL3841371 | 0.85 | PARP14 (0.46) | KDM4EDRD4DRD2DRD3MEN1 | |
| SCHEMBL3741042 | 0.85 | HSD17B10 (0.57) | LMNATSHRKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL10330203 | 0.81 | BRD4 (0.56) | LMNATSHRKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL3845055 | 0.79 | PDGFRB (0.44) | HRH4PDGFRBFGFR1KDR | |
| SCHEMBL29666061 | 0.78 | HSD17B10 (0.54) | LMNATSHRKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL23010423 | 0.76 | KDM4E (0.59) | LMNAKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL985935 | 0.76 | HSD17B10 (0.57) | LMNATSHRKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL29666112 | 0.76 | HSD17B10 (0.54) | LMNATSHRKDM4ESMN1; SMN2DRD4 | |
| SCHEMBL29666090 | 0.76 | HSD17B10 (0.54) | LMNATSHRKDM4ESMN1; SMN2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888556-B1 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-1313734-B1 | AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-11-11 | — | — | EP | disclosed |
| US-7368459-B2 | Heterocyclic compounds | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070032528-A1 | Heterocyclic compounds | RENHOWE PAUL A | 2007-02-08 | — | — | US | disclosed |
| US-7138409-B2 | Heterocyclic compounds | CHIRON CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| US-20050137188-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2005-06-23 | — | — | US | disclosed |
| US-6759417-B2 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS; SUCH AS 7-AMINO-6-(1H-BENZIMIDAZOL-2-YL)-3,4-DIHYDRO-5H-IMIDAZO(4,5-B)PYRIDIN-5-ONE | CHIRON CORPORATION | 2004-07-06 | — | — | US | disclosed |
| US-6756383-B2 | SUCH AS 3-(2-(METHOXYCARBONYL)ACETYLAMINO)PYRIDINE-4-CARBOXYLIC ACID FOR TREATMENT OF DISEASES CHARACTERIZED BY ACTIVITY OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASES; ENZYME INHIBITORS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| US-20040002518-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2004-01-01 | — | — | US | disclosed |
| US-20020103230-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103230-A1 | Heterocyclic compounds | SLCO2A1, SLCO1B1, SLCO2B1 | LMNA 2552/4885TSHR 1556/4885KDM4E 4366/4885 |
| US-20070032528-A1 | Heterocyclic compounds | SLCO4C1, SLCO2B1, SLCO1B1 | LMNA 3055/4885TSHR 1033/4885KDM4E 3580/4885 |
| US-20050137188-A1 | Heterocyclic compounds | SLCO4C1, SLCO2B1, SLCO1B1 | LMNA 3055/4885TSHR 1033/4885KDM4E 3580/4885 |
| US-20040002518-A1 | Heterocyclic compounds | SLCO2A1, SLCO1B1, SLCO2B1 | LMNA 2552/4885TSHR 1556/4885KDM4E 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.